Abstract 4317
Background
Adenocarcinoma of esophagogastric junction (AEG) is a special type of malignant tumor which occurs in the upper gastrointestinal tract. However, AEG is different from esophageal or gastric cancer. Its biological behavior is complicated and prognosis is poor. Even after radical resection, the overall 5-year survival rate is still very low. An in-depth analysis of the prognostic factors in patients with AEG may indicate a certain direction for clinical treatment and decision-making as well as for improving the prognosis of patients with AEG. Although some researchers have explored the factors influencing the prognosis of AEG, the independent prognostic factors are still unclear, which need to be further studied.
Methods
The clinical data of patients with AEG who underwent surgical treatment in PLA general hospital from January 2009 to January 2013 were collected retrospectively. According to the inclusion and exclusion criteria, a total of 343 patients with AEG were included in the study. Sex, age, basic disease, Siewert classification, tumor size (Diameter), differentiation, vascular cancer thrombus, nerve invasion, T-stage,N stage, pTNM, approach, minimally invasive surgery, resection scope, adjuvant chemotherapy, HER-2 and Ki-67 expression were analyzed comprehensively to study the independent or nonindependent prognostic factors in patients with AEG.
Results
The median follow-up time of the 343 patients with AEG was 50.2 months. The 5-year overall survival rate of the whole group (no IV stage) was 49.2%. Univariate analysis showed that age, basic disease, Siewert classification, tumor size (Diameter), differentiation, vascular cancer thrombus, nerve invasion, T-stage,N stage, pTNM, adjuvant chemotherapy, level of Ki-67 expression was correlated with prognosis (P < 0 05). Multivariate analysis showed that age, tumor size(Diameter), differentiation, pTNM and adjuvant chemotherapy were independent prognostic factors affecting the overall survival of the patients (P < 0 05).
Conclusions
The age, tumor size (Diameter), differentiation degree, pTNM and adjuvant chemotherapy were independent prognostic factors affecting the overall survival rate of patients with AEG (P < 0 05).
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Wangxinxin.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2674 - Multicenter Phase I Trial of Trastuzumab Emtansine (T-DM1) in Combination with Non-Pegylated Liposomal Doxorubicin (NPLD) in HER2[+] Metastatic Breast Cancer (MBC). THELMA Study
Presenter: Elena López-Miranda
Session: Poster Display session 2
Resources:
Abstract
1398 - Phase 1 study of liposomal formulation of eribulin (E7389-LF) in patients (pts) with advanced solid tumors: primary results of dose-escalation part
Presenter: Noboru Yamamoto
Session: Poster Display session 2
Resources:
Abstract
5818 - Polo-like Kinase 1 inhibitor onvansertib synergizes with paclitaxel in breast cancer carrying p53 mutation
Presenter: Antonio Giordano
Session: Poster Display session 2
Resources:
Abstract
5927 - Phase 1b study of heat shock protein 90 inhibitor, onalespib in combination with paclitaxel in patients with advanced, triple negative breast cancer (NCT02474173).
Presenter: Robert Wesolowski
Session: Poster Display session 2
Resources:
Abstract
1695 - Impact of pertuzumab and T-DM1 on prognosis of HER2-positive metastatic breast cancer (MBC) and factors affecting their efficacy: results from the AGMT_MBC-Registry
Presenter: Simon Peter Gampenrieder
Session: Poster Display session 2
Resources:
Abstract
1742 - Clinical profile and outcome of HER2 positive breast cancer patients with brain metastases treated with HER2 targeted therapy: Real world experience.
Presenter: Prabhat Bhargava
Session: Poster Display session 2
Resources:
Abstract
1846 - Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer: results of single arm phase IV COMACHI study
Presenter: Norikazu Masuda
Session: Poster Display session 2
Resources:
Abstract
5385 - Anti HER-2 Therapies and Left Ventricular Dysfunction The Renaissance Study
Presenter: ANDRES DANIELE
Session: Poster Display session 2
Resources:
Abstract
3320 - Safety and efficacy of T-DM1 in 128 patients with advanced HER2+ breast cancer: The Royal Marsden experience.
Presenter: Nicolò Battisti
Session: Poster Display session 2
Resources:
Abstract
4540 - Use of trastuzumab emtansine (T-DM1; K) after pertuzumab + trastuzumab (PH) in patients with HER2-positive metastatic breast cancer (mBC): challenges in assessing effectiveness of treatment sequencing in the real world (RW)
Presenter: Thibaut Sanglier
Session: Poster Display session 2
Resources:
Abstract